|1.||Ferguson, Mark W J: 5 articles (08/2009 - 10/2005)|
|2.||O'Kane, Sharon: 5 articles (08/2009 - 03/2007)|
|3.||Catherino, William H: 4 articles (03/2010 - 07/2004)|
|4.||Garcia-Closas, Montserrat: 3 articles (04/2014 - 06/2010)|
|5.||Malik, Minnie: 3 articles (03/2010 - 09/2008)|
|6.||Martínez-Alvarez, Concepción: 3 articles (04/2008 - 05/2002)|
|7.||Murray, Jeffrey C: 3 articles (08/2005 - 05/2003)|
|8.||Longaker, M T: 3 articles (07/2001 - 11/2000)|
|9.||Rienhoff, Hugh Young: 2 articles (08/2014 - 08/2013)|
|10.||Brinton, Louise A: 2 articles (04/2014 - 06/2010)|
08/01/2009 - "Extensive research into the mechanisms of scar-free and scar-forming healing has provided a robust scientific rationale for the development of avotermin (human recombinant TGF-beta3) as a potential therapeutic for the improvement of scar appearance in humans. "
03/01/1995 - "This study also suggests a novel therapeutic use of exogenous recombinant, TGF-beta 3 as an anti-scarring agent."
06/01/2010 - "Microarray analysis showed that TGF-beta3, an essential marker for preventing scarring, was upregulated and expressed for 2 weeks postoperatively. "
08/01/2009 - "As recombinant human TGF-beta3 (avotermin) is being developed for the improvement of scarring in the skin it is important to understand the role, if any, of this cytokine in tumour progression. "
04/11/2009 - "Research into mechanisms of skin scarring identified transforming growth factor beta3 (TGFbeta3) as a potential antiscarring therapy. "
08/01/1998 - "Experimental studies with TGF-beta 3, a potent negative regulator of epithelial and haematopoietic stem cell growth, have shown that it is possible to temporarily arrest oral mucosal basal cell proliferation, and could therefore offer a new effective and safe form of preventative intervention for patients about to undergo aggressive regimens of cancer therapy."
12/28/2012 - "These studies identify IL-1B and TGFB3 as pro-invasive factors in NSCLC and potential therapeutic targets for tumor progression."
10/01/2010 - "On the top 500 list, several cancer-related genes with an unrecognized role in VSs were down-regulated: CAV1, TGFB3, VCAM1, GLI1, GLI2, PRKAR2B, EPHA4, and FZD1. "
08/01/2009 - "TGF-beta3 and cancer: a review."
04/18/2008 - "In tumors arising in RB-positive livers, Cdkn2d and Tgfb1 were repressed and Cdkn2c, Tgfb2, Tgfb3 and Pai1 were induced, whereas in RB-negative tumors, only Cdkn2c and Tgfb3 were induced. "
|3.||Breast Neoplasms (Breast Cancer)
06/01/2011 - "Here associations with risk of invasive breast cancer are assessed for single-nucleotide polymorphisms (SNP) tagging 17 genes in the canonical TGF-β ALK5/SMADs 2&3 and ALK1/SMADs 1&5 signaling pathways: LTBP1, LTBP2, LTBP4, TGFB1, TGFB2, TGFB3, TGFBR1(ALK5), ALK1, TGFBR2, Endoglin, SMAD1, SMAD2, SMAD3, SMAD4, SMAD5, SMAD6, and SMAD7 [Approved Human Gene Nomenclature Committee gene names: ACVRL1 (for ALK1) and ENG (for Endoglin)]. "
05/15/1999 - "Our data support the hypothesis that methylation of a limited number of CpGs at the periphery of an otherwise unmethylated CpG island underlies the transcriptional repression of the downstream promoter in non-breast cancer cells, thereby serving to regulate the use of alternative promoters for TGF-beta3."
11/01/2000 - "The fact that it has been reported previously that high TGF beta 3 plasma levels in patients with untreated early stage breast cancer were correlated with subsequent lymph node metastasis and it was observed in the present study too, that TGF beta 3 expression in breast tumours was an independent predictor of overall survival, led us to suggest that the simultaneous measurement of TGF beta 3 in plasma and its expression in resected tumour tissues in the same cohort of patients may prove to be an important parameter in assessing tumour progression."
10/23/1998 - "Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer."
05/15/1999 - "Activation of an alternative downstream promoter, leading to the production of a truncated mRNA lacking the portion of the 5' noncoding region responsible for translational inhibition of TGF-beta3 mRNA, is only evident in breast cancer cells. "
06/01/1999 - "TGF-beta3 mouthwashes were well tolerated and deserve further study in preventing chemotherapy-induced mucositis."
06/01/1999 - "The purpose of this study was to establish the safety and tolerability of recombinant transforming growth factor-beta3 (TGF-beta3; CGP 46614) mouthwashes intended for prevention of chemotherapy-induced mucositis. "
02/01/2005 - "Keratinocyte growth factor, molgromastim, and transforming growth factor beta3 may also reduce chemotherapy-induced mucositis. "
01/01/1997 - "Administration of topical TGF-beta 3 prior to chemotherapy with 5-fluorouracil (5-FU) significantly reduced the severity of mucositis with respect to time, reduced chemotherapy-associated weight loss and increased survival."
10/01/2000 - "Data from trials in animal models and preliminary data in patients indicate that cytokines such as interleukin-1, interleukin-11, TGF-beta 3 and keratinocyte growth factor could reduce the incidence of mucositis. "
04/01/2002 - "Of clinical significance, umbilical cords from pregnancies complicated by pre-eclampsia, showed a significant reduction in total TGF-beta 3 protein expression when compared to those of age-matched patients. "
01/01/2002 - "Recent data obtained from studies on placenta suggest that temporal changes in expression of TGF-beta3 play a key role in trophoblast invasion and that over-expression of TGF-beta3 in pre-eclampsia is responsible for inadequate trophoblast invasion. "
04/01/2002 - "Our data demonstrate that during umbilical cord development TGF-beta 3 expression is spatially and temporally regulated and that TGF-beta 3 expression is altered in umbilical cords of pregnancies complicated by pre-eclampsia. "
04/01/2002 - "TGF-beta 3 expression during umbilical cord development and its alteration in pre-eclampsia."
06/01/1999 - "We speculate that a failure to downregulate expression of TGF-beta 3 at around 9 weeks' gestation results in shallow trophoblast invasion and predisposes the pregnancy to preeclampsia."
|1.||Transforming Growth Factor beta1 (TGF beta 1)
|2.||Transforming Growth Factor beta (TGF-beta)
|3.||Transforming Growth Factor beta2
|4.||Transforming Growth Factors (Transforming Growth Factor)
|8.||Messenger RNA (mRNA)
|9.||Protein Isoforms (Isoforms)
|10.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|1.||Drug Therapy (Chemotherapy)
|5.||Homologous Transplantation (Allograft)